Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Real-Life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile

    Journal Title:  Am J Hematol Primary Author:  Breccia M Author(s):  Breccia M...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

    Journal Title:  Leukemia Primary Author:  Platzbecker U Author(s):  Platzbeck...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. 5'-Azacitidine in myelodysplastic syndromes with inversion of chromosome 3.

    Journal Title:  Leukemia Primary Author:  Breccia M Author(s):  Breccia M, Ca...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine

    ... Center Clinical Database who received lenalidomide and azacitidine after ESA treatment failure. Rates of erythroid hematologic ... in patients who received lenalidomide first followed by azacitidine (group 1) and those who received lenalidomide after azacitidine ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.

    ... describing common adverse events (AEs) associated with azacitidine and methods to manage them. METHODS: In the Cancer ... (FAB) subtype of MDS were randomized to azacitidine or best supportive care (BSC). After 56 d, patients ... to BSC with disease progression could cross over to receive azacitidine. In the AZA-001 study, patients with higher-risk MDS (FAB-defined ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

    ... retrospective cohort of 282 higher-risk MDS treated with azacitidine , including 32 patients who concomitantly received an ESA for a median of 5.8months after azacitidine onset. Forty-four percent of ESA and 29% of no-ESA patients reached ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?

    ... Braulke F, Kündgen A et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk ... even if used, unfortunately yield low responses. While azacitidine prolongs survival in patients with HR-MDS by a median of 9.5 ... responses only occur in less than half of the patients, and azacitidine therapy is not curative, with most patients relapsing within 2 ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine

    ... Abstract The hypomethylating agents azacitidine and decitabine are standard therapy for ... who were treated with decitabine after primary or secondary azacitidine failure at the University of Maryland Greenebaum Cancer Center. ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial.

    ... The phase III AZA-001 study established that azacitidine significantly improves overall survival compared with ... disease progression). Achieving an Overall Response with azacitidine reduced risk of death by 95% compared with achieving an Overall ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes

    ... reported to identify differential survival among azacitidine -treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a ...

    Research Article last updated 07/20/2018 - 5:15pm.